No Data
No Data
The quarterly report verifies the strong growth in performance, why is Aimeike (300896.SZ) making strong players stronger?
In recent years, with the improvement of living standards, people have begun to pursue a higher level of spiritual life, and the face value economy has made great strides. According to a report published by Tencent Marketing Insights, the Chinese medical beauty market has grown at a compound annual growth rate of 17.5% since 2017 to nearly 190 billion dollars in 2021. However, due to multiple factors such as changes in residents' income expectations, the growth rate of medical and aesthetic consumption began to slow in 2022. The Zhitong Finance App notes that under the pessimistic expectations of the market, medicine and beauty have been questioned a lot over the past year or so as an “improved” optional consumption.
Ameke (300896.SZ) announced first-quarter results, net profit of 527 million yuan, an increase of 27.38%
According to the Zhitong Finance App, Aimeike (300896.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 808 million yuan, an increase of 28.24% over the previous year. Net profit attributable to shareholders of listed companies was $527 million, an increase of 27.38% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $528 million, an increase of 36.53% over the previous year.
Aimeike (300896.SZ) plans to transfer 10 shares to 4 shares and send 23.23 yuan to cut interest on April 29
Ameke (300896.SZ) announced that the company plans to pay 23.23 yuan (tax included) for every 10 shares to all shareholders,...
Could The Market Be Wrong About Imeik Technology Development Co.,Ltd. (SZSE:300896) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Imeik Technology DevelopmentLtd's (SZSE:300896) recent performance, when its stock has declined 18% over the past month. However, stock prices are usually
The actual controllers of Ameke have made a profit, but what about shareholders?
“Investor Network” How profitable can a Jordan woman's face business be? From 2014 to 2023, Aimeike (300896.SZ), a “women's Maotai”, achieved leaps and bounds in performance by relying on products with a unit cost of only 20 to 30 yuan. The revenue scale increased from 75 million yuan to 2.9 billion yuan, and net profit also climbed from 28 million yuan to 1.9 billion yuan. Although the beautiful economy is attractive, the capital market is not an easy path. Aimeike went public with an overfunding of 1.5 billion yuan. At the beginning of its listing, it was enthusiastically sought after by the market, but now its market value has shrunk drastically, falling to more than 220 billion yuan. Not listed
Aimeike (300896.SZ): Pre-increase non-net profit by more than 30% in 2024Q1, forward-looking layout of the Blue Ocean Circuit
Aimeike, known as the “medical beauty”, seems to have recently faced quite a few challenges in the A-share market. Since April, its stock price has retreated nearly 15%, and its PE (TTM) has fallen to 34.67 times, setting a new low since listing. Naturally, this situation has attracted widespread attention in the market. (Data closes on April 9) However, when we delved deeper into the company's recently released earnings data, we saw a different picture. According to the 2023 annual report and the forecast for the first quarter of 2024, Aimec showed a steady growth trend. In 2023, the company achieved revenue of 2,869 billion yuan
No Data